Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Rheumatic Fever HELP
Based on 2,011 articles published since 2010
||||

These are the 2011 published articles about Rheumatic Fever that originated from Worldwide during 2010-2020.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline Seven key actions to eradicate rheumatic heart disease in Africa: the Addis Ababa communiqué. 2016

Watkins, David / Zuhlke, Liesl / Engel, Mark / Daniels, Rezeen / Francis, Veronica / Shaboodien, Gasnat / Kango, Mabvuto / Abul-Fadl, Azza / Adeoye, Abiodun / Ali, Sulafa / Al-Kebsi, Mohammed / Bode-Thomas, Fidelia / Bukhman, Gene / Damasceno, Albertino / Goshu, Dejuma Yadeta / Elghamrawy, Alaa / Gitura, Bernard / Haileamlak, Abraham / Hailu, Abraha / Hugo-Hamman, Christopher / Justus, Steve / Karthikeyan, Ganesan / Kennedy, Neil / Lwabi, Peter / Mamo, Yoseph / Mntla, Pindile / Sutton, Chris / Mocumbi, Ana Olga / Mondo, Charles / Mtaja, Agnes / Musuku, John / Mucumbitsi, Joseph / Murango, Louis / Nel, George / Ogendo, Stephen / Ogola, Elijah / Ojji, Dike / Olunuga, Taiwo Olabisi / Redi, Mekia Mohammed / Rusingiza, Kamanzi Emmanuel / Sani, Mahmoud / Sheta, Sahar / Shongwe, Steven / van Dam, Joris / Gamra, Habib / Carapetis, Jonathan / Lennon, Diana / Mayosi, Bongani M. ·Department of Medicine, Groote Schuur Hospital and University of Cape Town, South Africa; University of Washington, USA. · Department of Medicine, Groote Schuur Hospital and University of Cape Town, South Africa. · African Union Commission, Ethiopia. · Association Friends of Children with RHD, Egypt. · University College Hospital, Ibadan, Nigeria. · University of Khartoum and Sudan Heart Centre, Sudan. · University of Sana'a, Yemen. · University of Jos, Nigeria. · Harvard Medical School/Partners in Health, USA. · Mozambican Heart Association (AMOCOR), Mozambique. · Addis Ababa University, Ethiopia. · Ministry of Health, Rheumatic Heart Disease Programme, NCDs, Egypt. · Kenyatta National Hospital, Kenya. · Jimma University, Ethiopia. · Mekelle University, Ethiopia. · Ministry of Health and Social Services, Namibia. · Touch Foundation, Tanzania. · All India Institute of Medical Sciences, India. · College of Medicine, University of Malawi, Malawi. · Uganda Heart Institute, Uganda. · Technical Adviser, NCD directorate, Federal Ministry of Health of Ethiopia, Ethiopia. · Sefako Makgatho Health Sciences University, South Africa. · Instituto Nacional de Saúde, Mozambique and PASCAR Vice President South. · Mulago Hospital, Uganda. · University Teaching Hospital, Zambia. · Rwanda Heart Foundation, Rwanda. · East African Community, Burundi. · PASCAR Secretariat, South Africa. · University of Nairobi, Kenya. · University of Abuja Teaching Hospital, Nigeria. · Federal Medical Centre, Abeokuta, Nigeria. · Common Market for Eastern and Southern Africa, Ethiopia. · University of Rwanda, Rwanda. · Bayero University Kano and Aminu Kano Teaching Hospital, Nigeria. · Cairo University Children Hospital, Faculty of Medicine, Egypt. · WHO Regional Office in Africa, Congo. · Novartis, USA. · African Heart Network, Tunisia. · Telethon Kids Institute, University of Western Australia, Princess Margaret Hospital for Children, Australia. · University of Auckland, New Zealand. · Department of Medicine, Groote Schuur Hospital and University of Cape Town, South Africa; PASCAR Secretariat, South Africa. bongani.mayosi@uct.ac.za. ·Cardiovasc J Afr · Pubmed #26815006.

ABSTRACT: Acute rheumatic fever (ARF) and rheumatic heart disease (RHD) remain major causes of heart failure, stroke and death among African women and children, despite being preventable and imminently treatable. From 21 to 22 February 2015, the Social Cluster of the Africa Union Commission (AUC) hosted a consultation with RHD experts convened by the Pan-African Society of Cardiology (PASCAR) in Addis Ababa, Ethiopia, to develop a 'roadmap' of key actions that need to be taken by governments to eliminate ARF and eradicate RHD in Africa. Seven priority areas for action were adopted: (1) create prospective disease registers at sentinel sites in affected countries to measure disease burden and track progress towards the reduction of mortality by 25% by the year 2025, (2) ensure an adequate supply of high-quality benzathine penicillin for the primary and secondary prevention of ARF/RHD, (3) improve access to reproductive health services for women with RHD and other non-communicable diseases (NCD), (4) decentralise technical expertise and technology for diagnosing and managing ARF and RHD (including ultrasound of the heart), (5) establish national and regional centres of excellence for essential cardiac surgery for the treatment of affected patients and training of cardiovascular practitioners of the future, (6) initiate national multi-sectoral RHD programmes within NCD control programmes of affected countries, and (7) foster international partnerships with multinational organisations for resource mobilisation, monitoring and evaluation of the programme to end RHD in Africa. This Addis Ababa communiqué has since been endorsed by African Union heads of state, and plans are underway to implement the roadmap in order to end ARF and RHD in Africa in our lifetime.

2 Guideline Infective Endocarditis in Childhood: 2015 Update: A Scientific Statement From the American Heart Association. 2015

Baltimore, Robert S / Gewitz, Michael / Baddour, Larry M / Beerman, Lee B / Jackson, Mary Anne / Lockhart, Peter B / Pahl, Elfriede / Schutze, Gordon E / Shulman, Stanford T / Willoughby, Rodney / Anonymous5840842. · ·Circulation · Pubmed #26373317.

ABSTRACT: -- No abstract --

3 Guideline Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. 2015

Baddour, Larry M / Wilson, Walter R / Bayer, Arnold S / Fowler, Vance G / Tleyjeh, Imad M / Rybak, Michael J / Barsic, Bruno / Lockhart, Peter B / Gewitz, Michael H / Levison, Matthew E / Bolger, Ann F / Steckelberg, James M / Baltimore, Robert S / Fink, Anne M / O'Gara, Patrick / Taubert, Kathryn A / Anonymous5830842. · ·Circulation · Pubmed #26373316.

ABSTRACT: BACKGROUND: Infective endocarditis is a potentially lethal disease that has undergone major changes in both host and pathogen. The epidemiology of infective endocarditis has become more complex with today's myriad healthcare-associated factors that predispose to infection. Moreover, changes in pathogen prevalence, in particular a more common staphylococcal origin, have affected outcomes, which have not improved despite medical and surgical advances. METHODS AND RESULTS: This statement updates the 2005 iteration, both of which were developed by the American Heart Association under the auspices of the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease of the Young. It includes an evidence-based system for diagnostic and treatment recommendations used by the American College of Cardiology and the American Heart Association for treatment recommendations. CONCLUSIONS: Infective endocarditis is a complex disease, and patients with this disease generally require management by a team of physicians and allied health providers with a variety of areas of expertise. The recommendations provided in this document are intended to assist in the management of this uncommon but potentially deadly infection. The clinical variability and complexity in infective endocarditis, however, dictate that these recommendations be used to support and not supplant decisions in individual patient management.

4 Guideline Revision of the Jones Criteria for the diagnosis of acute rheumatic fever in the era of Doppler echocardiography: a scientific statement from the American Heart Association. 2015

Gewitz, Michael H / Baltimore, Robert S / Tani, Lloyd Y / Sable, Craig A / Shulman, Stanford T / Carapetis, Jonathan / Remenyi, Bo / Taubert, Kathryn A / Bolger, Ann F / Beerman, Lee / Mayosi, Bongani M / Beaton, Andrea / Pandian, Natesa G / Kaplan, Edward L / Anonymous420828. · ·Circulation · Pubmed #25908771.

ABSTRACT: BACKGROUND: Acute rheumatic fever remains a serious healthcare concern for the majority of the world's population despite its decline in incidence in Europe and North America. The goal of this statement was to review the historic Jones criteria used to diagnose acute rheumatic fever in the context of the current epidemiology of the disease and to update those criteria to also take into account recent evidence supporting the use of Doppler echocardiography in the diagnosis of carditis as a major manifestation of acute rheumatic fever. METHODS AND RESULTS: To achieve this goal, the American Heart Association's Council on Cardiovascular Disease in the Young and its Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee organized a writing group to comprehensively review and evaluate the impact of population-specific differences in acute rheumatic fever presentation and changes in presentation that can result from the now worldwide availability of nonsteroidal anti-inflammatory drugs. In addition, a methodological assessment of the numerous published studies that support the use of Doppler echocardiography as a means to diagnose cardiac involvement in acute rheumatic fever, even when overt clinical findings are not apparent, was undertaken to determine the evidence basis for defining subclinical carditis and including it as a major criterion of the Jones criteria. This effort has resulted in the first substantial revision to the Jones criteria by the American Heart Association since 1992 and the first application of the Classification of Recommendations and Levels of Evidence categories developed by the American College of Cardiology/American Heart Association to the Jones criteria. CONCLUSIONS: This revision of the Jones criteria now brings them into closer alignment with other international guidelines for the diagnosis of acute rheumatic fever by defining high-risk populations, recognizing variability in clinical presentation in these high-risk populations, and including Doppler echocardiography as a tool to diagnose cardiac involvement.

5 Guideline 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014

Nishimura, Rick A / Otto, Catherine M / Bonow, Robert O / Carabello, Blase A / Erwin, John P / Guyton, Robert A / O'Gara, Patrick T / Ruiz, Carlos E / Skubas, Nikolaos J / Sorajja, Paul / Sundt, Thoralf M / Thomas, James D / Anderson, Jeffrey L / Halperin, Jonathan L / Albert, Nancy M / Bozkurt, Biykem / Brindis, Ralph G / Creager, Mark A / Curtis, Lesley H / DeMets, David / Guyton, Robert A / Hochman, Judith S / Kovacs, Richard J / Ohman, E Magnus / Pressler, Susan J / Sellke, Frank W / Shen, Win-Kuang / Stevenson, William G / Yancy, Clyde W / Anonymous5160797 / Anonymous5170797 / Anonymous5180797. · ·J Thorac Cardiovasc Surg · Pubmed #24939033.

ABSTRACT: -- No abstract --

6 Guideline Position statement of the World Heart Federation on the prevention and control of rheumatic heart disease. 2013

Remenyi, Bo / Carapetis, Jonathan / Wyber, Rosemary / Taubert, Kathryn / Mayosi, Bongani M / Anonymous3560754. ·World Heart Federation, 7 rue des Battoirs, Case Postale 155, 1211 Geneva 4, Switzerland. ·Nat Rev Cardiol · Pubmed #23546444.

ABSTRACT: In the 21(st) century, rheumatic fever (RF) and rheumatic heart disease (RHD) are neglected diseases of marginalized communities. Globally, RHD remains the most-common cardiovascular disease in young people aged <25 years. Although RF and RHD have been almost eradicated in areas with established economies, migration from low-income to high-income settings might be responsible for a new burden of RHD in high-income countries. The World Heart Federation (WHF) and its Working Group on RF and RHD unites global experts, combines their experience and enthusiasm, and provides a platform for RHD control. This paper is a declaration of the WHF institutional strategic goal--a 25% reduction in premature deaths from RF and RHD among individuals aged <25 years by the year 2025. The position statement affirms WHF commitments to five key strategic targets: comprehensive register-based control programmes, global access to benzathine penicillin G, identification and development of public figures as 'RHD champions', expansion of RHD training hubs, and support for vaccine development. In this paper, we also review existing barriers to RF and RHD control and identify the actions required to change the trajectory of control for these diseases. This approach provides the foundation for governments, civil society, patient advocates, clinicians, researchers, and funding agencies to develop partnerships and unify global efforts to control RF and RHD. The WHF plans to expand this position statement to an operational plan that will be founded on science, research, and quantifiable progress indicators to impact positively on the millions of people who are affected by RHD and its long-term sequelae.

7 Guideline [Guidelines on the management of valvular heart disease (version 2012). The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)]. 2013

Vahanian, Alec / Alfieri, Ottavio / Andreotti, Felicita / Antunes, Manuel J / Baron-Esquivias, Gonzalo / Baumgartner, Helmut / Borger, Michael Andrew / Carrel, Thierry P / De Bonis, Michele / Evangelista, Arturo / Falk, Volkmar / Iung, Bernard / Lancellotti, Patrizio / Pierard, Luc / Price, Susanna / Schafers, Hans-Joachim / Schuler, Gerhard / Stepinska, Janina / Swedberg, Karl / Takkenberg, Johanna / Von Oppell, Ulrich Otto / Windecker, Stephan / Zamorano, Jose Luis / Zembala, Marian / Anonymous2170752. · ·G Ital Cardiol (Rome) · Pubmed #23474606.

ABSTRACT: -- No abstract --

8 Guideline Guidelines on the management of valvular heart disease (version 2012). 2012

Anonymous1070735 / Anonymous1080735 / Vahanian, Alec / Alfieri, Ottavio / Andreotti, Felicita / Antunes, Manuel J / Barón-Esquivias, Gonzalo / Baumgartner, Helmut / Borger, Michael Andrew / Carrel, Thierry P / De Bonis, Michele / Evangelista, Arturo / Falk, Volkmar / Iung, Bernard / Lancellotti, Patrizio / Pierard, Luc / Price, Susanna / Schäfers, Hans-Joachim / Schuler, Gerhard / Stepinska, Janina / Swedberg, Karl / Takkenberg, Johanna / Von Oppell, Ulrich Otto / Windecker, Stephan / Zamorano, Jose Luis / Zembala, Marian. ·Service de Cardiologie, Hospital Bichat AP-HP, 46 rue Henri Huchard, 75018 Paris, France. alec.vahanian@bch.aphp.fr ·Eur Heart J · Pubmed #22922415.

ABSTRACT: -- No abstract --

9 Guideline Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 2012

Whitlock, Richard P / Sun, Jack C / Fremes, Stephen E / Rubens, Fraser D / Teoh, Kevin H. ·McMaster University, Hamilton, ON, Canada. Electronic address: richard.whitlock@phri.ca. · University of Washington School of Medicine, Seattle, WA. · Sunnybrook Hospital, University of Toronto, Toronto, ON, Canada. · Ottawa Heart Institute, Ottawa, ON, Canada. · McMaster University, Hamilton, ON, Canada. ·Chest · Pubmed #22315272.

ABSTRACT: BACKGROUND: Antithrombotic therapy in valvular disease is important to mitigate thromboembolism, but the hemorrhagic risk imposed must be considered. METHODS: The methods of this guideline follow those described in Methodology for the Development of Antithrombotic Therapy and Prevention of Thrombosis Guidelines. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines in this supplement. RESULTS: In rheumatic mitral disease, we recommend vitamin K antagonist (VKA) therapy when the left atrial diameter is > 55 mm (Grade 2C) or when complicated by left atrial thrombus (Grade 1A). In candidates for percutaneous mitral valvotomy with left atrial thrombus, we recommend VKA therapy until thrombus resolution, and we recommend abandoning valvotomy if the thrombus fails to resolve (Grade 1A). In patients with patent foramen ovale (PFO) and stroke or transient ischemic attack, we recommend initial aspirin therapy (Grade 1B) and suggest substitution of VKA if recurrence (Grade 2C). In patients with cryptogenic stroke and DVT and a PFO, we recommend VKA therapy for 3 months (Grade 1B) and consideration of PFO closure (Grade 2C). We recommend against the use of anticoagulant (Grade 1C) and antiplatelet therapy (Grade 1B) for native valve endocarditis. We suggest holding VKA therapy until the patient is stabilized without neurologic complications for infective endocarditis of a prosthetic valve (Grade 2C). In the first 3 months after bioprosthetic valve implantation, we recommend aspirin for aortic valves (Grade 2C), the addition of clopidogrel to aspirin if the aortic valve is transcatheter (Grade 2C), and VKA therapy with a target international normalized ratio (INR) of 2.5 for mitral valves (Grade 2C). After 3 months, we suggest aspirin therapy (Grade 2C). We recommend early bridging of mechanical valve patients to VKA therapy with unfractionated heparin (DVT dosing) or low-molecular-weight heparin (Grade 2C). We recommend long-term VKA therapy for all mechanical valves (Grade 1B): target INR 2.5 for aortic (Grade 1B) and 3.0 for mitral or double valve (Grade 2C). In patients with mechanical valves at low bleeding risk, we suggest the addition of low-dose aspirin (50-100 mg/d) (Grade 1B). In valve repair patients, we suggest aspirin therapy (Grade 2C). In patients with thrombosed prosthetic valve, we recommend fibrinolysis for right-sided valves and left-sided valves with thrombus area < 0.8 cm(2) (Grade 2C). For patients with left-sided prosthetic valve thrombosis and thrombus area ≥ 0.8 cm(2), we recommend early surgery (Grade 2C). CONCLUSIONS: These antithrombotic guidelines provide recommendations based on the optimal balance of thrombotic and hemorrhagic risk.

10 Guideline Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA. 2011

Smolen, Josef S / Boers, Maarten / Abadie, Eric C / Breedveld, Ferdinand C / Emery, Paul / Bardin, Thomas / Goel, Niti / Ethgen, Dominique J / Avouac, Bernard P / Dere, Willard H / Durez, Patrick / Matucci-Cerinic, Marco / Flamion, Bruno / Laslop, Andrea / Lekkerkerker, Frits J / Miossec, Pierre / Mitlak, Bruce H / Ormarsdóttir, Sif / Paolozzi, Laurence / Rao, Ravi / Reiter, Susan / Tsouderos, Yannis / Reginster, Jean-Yves / Anonymous6461105. ·Hietzing Hospital, Vienna, Austria. ·Curr Med Res Opin · Pubmed #21142618.

ABSTRACT: Since 2003, the European Medicines Agency (EMA) document, 'Points to consider on clinical investigation of medicinal products other than NSAIDs (nonsteroidal anti-inflammatory drugs) for the treatment of rheumatoid arthritis' has provided guidance for the clinical development of both biologic and non-biologic disease-modifying antirheumatic drugs (DMARDs). In the last few years, several new products have been developed or are in development for the treatment of RA, which offer significant efficacy with regard to disease control, including prevention of structural damage and disability. Concurrently, novel insights have been gained with respect to the assessment of disease activity, joint damage and disability. New treatment strategies have been established which relate to early therapy, tight control and rapid switching of medication. Accordingly, several new EULAR/ACR recommendations have been or are being developed. Several important additions and changes are needed in the 2003 guidance to incorporate the current scientific knowledge into clinical trial design for the development of future products. Under the auspices of the Group for the Respect of Ethics and Excellence in Science (GREES), a group of experts in the field of RA and clinical trial design met to provide a consensus recommendation for an update to the 2003 EMA guidance document.

11 Editorial Mitral Valve Repair in Young Rheumatic Patients. 2019

Pomerantzeff, Pablo Maria Alberto. ·Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP - Brazil. · Unidade Cirúrgica de Cardiopatia Valvar - Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP - Brazil. ·Arq Bras Cardiol · Pubmed #31691757.

ABSTRACT: -- No abstract --

12 Editorial Rheumatic Fever in Brazil: What Color Should It Be? 2019

Longenecker, Chris T. ·University Hospitals Harrington Heart and Vascular Institute, Cleveland, Ohio - USA. · Case Western Reserve University School of Medicine, Cleveland, Ohio - USA. ·Arq Bras Cardiol · Pubmed #31621774.

ABSTRACT: -- No abstract --

13 Editorial Cardiac Surgery for the Forgotten Millions: The Way Forward. Cardiac Surgery Intersociety Alliance (CSIA) Site Selection Criteria. 2019

Boateng, Percy / Bolman, R Morton / Zilla, Peter / Anonymous2191053. ·Department of Cardiovascular Surgery, Icahn School of Medicine, Mount Sinai (ISMMS) Medical Center, New York, New York. Electronic address: percy.boateng@mountsinai.org. · University of Colorado Denver, Denver, Colorado; University of Colorado, Anschutz Medical Campus, Aurora, Colorado. · Christian Barnard Department for Cardiothoracic Surgery, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa. ·Ann Thorac Surg · Pubmed #31445591.

ABSTRACT: -- No abstract --

14 Editorial Cardiac surgery for the forgotten millions: The way forward. Cardiac Surgery Intersociety Alliance (CSIA) Site Selection Criteria. 2019

Boateng, Percy / Bolman, R Morton / Zilla, Peter / Anonymous1891102. ·Department of Cardiovascular Surgery, Icahn School of Medicine, Mount Sinai (ISMMS) Medical Center, New York, NY. Electronic address: percy.boateng@mountsinai.org. · University of Colorado Denver, Denver, Colo; University of Colorado, Anschutz Medical Campus, Aurora, Colo. · Christian Barnard Department for Cardiothoracic Surgery, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa. ·J Thorac Cardiovasc Surg · Pubmed #31324422.

ABSTRACT: -- No abstract --

15 Editorial Fighting Rheumatic Heart Disease: What are the next moves? 2019

Nascimento, Bruno Ramos / Beaton, Andrea Zawacki. ·Serviço de Cardiologia e Cirurgia Cardiovascular e Centro de Telessaúde, Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brasil. · Departamento de Clínica Médica, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brasil. · The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. · Division of Pediatrics, The Univeristy of Cincinnati School of Medicine, Cincinnati, OH, USA. ·Rev Soc Bras Med Trop · Pubmed #31271625.

ABSTRACT: -- No abstract --

16 Editorial Beyond Sharing and Shifting: Raising the Bar for Global Rheumatic Heart Disease Control. 2019

Lee, Scott S / Vedanthan, Rajesh. ·Department of Medicine and Institute for Global Health, Vanderbilt University, Nashville, TN, USA. Electronic address: ssl@mail.harvard.edu. · Section for Global Health, Department of Population Health, New York University School of Medicine, New York, NY, USA. ·Glob Heart · Pubmed #31113732.

ABSTRACT: -- No abstract --

17 Editorial Rheumatic heart disease: A neglected public health priority. 2019

Kumar, Rajesh. ·IJPH Advisory Board Member, Professor and Head, Department of Community Medicine, School of Public Health, Dean (Academic), Post Graduate Institute of Medical Education and Research, Chandigarh, India. ·Indian J Public Health · Pubmed #30880729.

ABSTRACT:

18 Editorial Commentary: The golden ratio. 2019

Timek, Tomasz A. ·Division of Cardiothoracic Surgery, Spectrum Health, Grand Rapids, Mich; Michigan State University College of Human Medicine, Grand Rapids, Mich. Electronic address: tomasz.timek@spectrumhealth.org. ·J Thorac Cardiovasc Surg · Pubmed #30772042.

ABSTRACT: -- No abstract --

19 Editorial Echo Screening for Rheumatic Heart Disease. 2019

Longenecker, Chris T. ·University Hospitals Harrington Heart & Vascular Institute and Case Western Reserve University School of Medicine, Cleveland, OH. ·Circ Cardiovasc Imaging · Pubmed #30704284.

ABSTRACT: -- No abstract --

20 Editorial Digoxin for rheumatic heart disease: a cautious future for a drug from the past? 2019

Nascimento, Bruno R / Beaton, Andrea Z. ·Serviço de Cardiologia e Cirurgia Cardiovascular e Centro de Telessaúde, Hospital das Clínicas da Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil. · Departamento de Clínica Médica, Faculdade de Medicina da Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil. · Cardiology Department, Children's National Health System, Washington, District of Columbia, USA. ·Heart · Pubmed #30314972.

ABSTRACT: -- No abstract --

21 Editorial From the Editor's Desk. 2018

Commerford, Pat. ·Editor-in-Chief. ·Cardiovasc J Afr · Pubmed #31199425.

ABSTRACT: -- No abstract --

22 Editorial Nonvalvular atrial fibrillation in India-time to pause, think, and change! 2018

Singh, Balbir. ·Department of Cardiology, Division of Cardiac Electrophysiology, Medanta-The Medicity, Sector 38, Gurgaon, 122001, India. Electronic address: drbalbirs@gmail.com. ·Indian Heart J · Pubmed #30580841.

ABSTRACT: -- No abstract --

23 Editorial Is Inflammasome a Potential Target of Prophylaxis in Rheumatic Heart Disease? 2018

Kuriakose, Teneema / Kanneganti, Thirumala-Devi. ·Department of Immunology, St Jude Children's Research Hospital, Memphis, TN. ·Circulation · Pubmed #30571276.

ABSTRACT: -- No abstract --

24 Editorial The Cape Town Declaration on access to cardiac surgery in the developing world. 2018

Zilla, Peter / Bolman, R Morton / Yacoub, Magdi H / Beyersdorf, Friedhelm / Sliwa, Karen / Zühlke, Liesl / Higgins, Robert S D / Mayosi, Bongani / Carpentier, Alain / Williams, David. ·Christiaan Barnard Division of Cardiothoracic Surgery, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa. Electronic address: peter.zilla@uct.ac.za. · Division of Cardiothoracic Surgery, University of Vermont, Burlington, Vt. · Chain of Hope, Chelsea, London, United Kingdom. · Department of Cardiovascular Surgery, Universitäts-Herzzentrum Freiburg-Bad Krotzingen, Freiburg, Germany. · Hatter Institute of Cardiovascular Research in Africa, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa. · Division of Pediatric Cardiology, Department of Pediatrics and Child Health, University of Cape Town, Cape Town, South Africa. · Department of Surgery, Johns Hopkins Medicine, Baltimore, Md. · Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa. · Hôpital Européen Georges Pompidou, Paris, France. · Wake Forest Institute of Regenerative Medicine, Wake Forest School of Medicine, Winston-Salem, NC. ·J Thorac Cardiovasc Surg · Pubmed #30082076.

ABSTRACT: -- No abstract --

25 Editorial Cardiovascular magnetic resonance imaging in rheumatic heart disease. 2018

Ntusi, N A. ·Division of Cardiology, Department of Medicine, University of Cape Town and Groote Schuur Hospital; Cape Universities Body Imaging Centre, Faculty of Health Sciences, University of Cape Town; Hatter Institute of Cardiovascular Research in Africa, Department of Medicine, University of Cape Town, South Africa. Email: ntobeko.ntusi@uct.ac.za. ·Cardiovasc J Afr · Pubmed #30067271.

ABSTRACT: -- No abstract --

Next